CSI Market
Sign In | Register

Kalvista Pharmaceuticals Inc (KALV) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access KALV quarterly Cash Flow →
A period-by-period view of cash flow from Kalvista Pharmaceuticals Inc to Apr 30 2021 helps clarify how Apr 30 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Apr 30 2025)
12 Months 		(Apr 30 2024) (Apr 30 2023) (Apr 30 2022) (Apr 30 2021)
Operating Activities
Income-183.44
Depreciation & amortization0.94
Amortization of Other Assets0.01
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation12.29
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Realized-4.18
Fair Value Adjustment Of Warrants And Derivative Liabilities-
Increase Decrease In Research And Development Tax Credit Receivable7.25
Available For Sale Securities Gross Realized Gain Loss Net-
Increase Decrease In Lease Obligations-
Marketable Securities Realized Gain Loss-
Non- Cash Interest Expense And Amortization Of Issuance Costs5.87
Fair Value Adjustment To Derivative Liability1.75
Non Cash Operating Lease Expense0.37
Operating Lease Right Of Use Asset Amortization Expense10.56
Increase Decrease In Accrued Expenses And Other Liabilities-
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total-1.56
Increase (Decrease) in Accounts Receivable-10.87
Increase (Decrease) in Accounts Payable-4.97
Increase (Decrease) in Accrued Liabilities14.43
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.36
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-152.91
Investing Activities
Capital Expenditures-0.93
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities122.52
Payments to Acquire Available-for-sale Securities, Debt-30.57
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities91.02
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock61.69
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net100.00
Conversion Of Stock Amount Converted-
Proceeds From Royalty Agreement-
Issuance Costs Associated With Royalty Agreement-1.96
Proceeds From The Royalty Agreement-
Issuance Of Common Stock From Employee Stock Purchase Plan-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities159.73
Effect of exchange rate on cash flow2.64
Discontinued operations0.00
Free Cash Flow-153.84
Total Cash Flow100.48
4 historic quarters locked

Sign in to unlock the full Kalvista Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Kalvista Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-25-095011

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License